CORINA LOHRMAN: Open Payments
NPI 1942826136 · ARVADA, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$957 in 39 payments from 10 companies in 2025. Trend: 2023 $425 · 2024 $1,210 · 2025 $957
Food & beverage: $957
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 18 | $514 |
| Novo Nordisk Inc | 5 | $125 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $75 |
| Lilly USA, LLC | 3 | $66 |
| Amgen Inc. | 3 | $59 |
| Organon LLC | 2 | $44 |
| Corcept Therapeutics | 1 | $30 |
| Phadia US Inc. | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $6 |
Products named: AIRSUPRA, Wegovy, Kerendia, NEXIUM, MOUNJARO, NEXPLANON, OTEZLA, Korlym.
Industry payments across CO — which companies pay providers there.
